Omar Abudayyeh is an Assistant Professor at Harvard Medical School, Investigator at Brigham and Women’s Hospital and Mass General Brigham’s Gene and Cell Therapy Institute, and faculty member with the Department of Stem Cell and Regenerative Biology at Harvard University. He directs the Abudayyeh-Gootenberg lab, which is developing next-generation gene editing, gene delivery, and synthetic biology technologies using protein engineering and artificial intelligence and applies them towards new therapeutics and the study of aging. He previously was a McGovern Fellow at MIT where he directed his own research group and before that was at Harvard Medical School and MIT as a graduate student in Feng Zhang’s lab at the Broad Institute, where he earned a Ph.D. researching novel CRISPR enzymes for genome editing, therapeutics, and diagnostics. He is a pioneer in the gene editing space as an inventor on dozens of patents and patent applications relating to gene editing and diagnostic innovations, as well as over 30,000 citations on more than 45 peer-reviewed articles in journals like Nature, Science, and Cell. He is also co-founder of Sherlock Biosciences, Proof Diagnostics (acquired), and Tome Biosciences, which are commercializing CRISPR-based diagnostics and therapeutics, as well as other stealth starts ups in the gene and RNA therapy space, which have collectively raised hundreds of millions. Dr. Abudayyeh has been recognized as Technology Review Innovators Under 35, Bloomberg New Economy Catalyst, Endpoints 20 under 40 Next Generation of Biotech Leaders, 2022 Termeer Scholar, 2018 Forbes 30 under 30, Business Insider 30 under 30, a 2018 TEDMED Hive honoree, and a 2013 Paul and Daisy Soros Fellow. Dr. Abudayyeh graduated from MIT in 2012 with a B.S. in mechanical engineering and biological engineering, where he was a Henry Ford II Scholar and a Barry M. Goldwater Scholar. He also spent two years studying towards an MD at Harvard Medical School.